Press Releases Camurus AB

Equities

CAMX

SE0007692850

Pharmaceuticals

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2026-04-17 pm EDT			5-day change	1st Jan Change
579.00 ^SEK	+2.30%		+12.54%	-6.01%

Apr. 07	Lancelot Sverige slips 5.7 percent in March - Asmodee expands through acquisition	FW
Mar. 23	96 stocks hit new 52-week lows on the Stockholm Stock Exchange so far today	FW

Press Releases

Feb. 27	Change in number of shares and votes in Camurus	AQ
Feb. 18	Camurus (Q4 review): Temporary UK Setback	AQ
Feb. 17	Camurus appoints Jane Buus Laursen as Chief Corporate Development Officer	AQ
Feb. 12	Camurus' Full Year Report 2025	AQ
Jan. 09	Camurus announces FDA acceptance of NDA resubmission for Oclaiz™ for the treatment of acromegaly	AQ
Dec. 16	Camurus and Gubra enter into a collaboration and license agreement to develop a long-acting treatment for hypoparathyroidism	AQ
Dec. 16	Gubra and Camurus Enter into a Collaboration and License Agreement to Develop a Long-acting Treatment for Hypoparathyroidism	AQ
Nov. 28	Change in number of shares and votes in Camurus	AQ
Nov. 13	Camurus' Nomination Committee appointed for the Annual General Meeting 2026	AQ
Nov. 12	Camurus to present at Jefferies London Healthcare Conference	AQ
Nov. 10	Camurus reports positive topline results for CAM2056, semaglutide monthly depot	AQ
Nov. 06	Camurus' Interim Report Third Quarter 2025	AQ
Nov. 03	Camurus launches long-acting Oczyesa® for the treatment of acromegaly	AQ
25-10-14	AcuCort strengthens its management team with the appointment of Anna Chérouvrier Hansson as Business Development Director	AQ
25-09-30	Change in number of shares and votes in Camurus	AQ
25-09-15	Exercise in Camurus' employee stock options program 2022/2026	AQ
25-08-28	Camurus announces approval of Oczyesa® for the treatment of acromegaly in the UK	AQ
25-07-24	Camurus CEO sells shares	AQ
25-07-22	Camurus Q2 2025 - Deal with Eli Lilly	AQ
25-07-17	Camurus' Interim Report Second Quarter 2025	AQ
25-07-01	Novel pre-filled autoinjector receives EU approval	AQ
25-07-01	Camurus' Oczyesa® receives marketing authorization for treatment of acromegaly in the EU	AQ
25-06-30	Change in number of shares and votes in Camurus	AQ
25-06-18	Camurus' POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients	AQ
25-06-12	Sandberg Development has sold 2,250,000 shares in Camurus	AQ